Literature DB >> 15479389

The target joint.

K Mulder1, A Llinás.   

Abstract

Bleeding into the joints is the most common manifestation of severe haemophiliacs. Although it may resolve spontaneously or with treatment, some patients find that one particular joint has recurrent bleeding; this is termed a target joint. Recurrent bleeding prevents the joint from regaining its range of motion, muscle strength and normal appearance. These changes become permanent, leading eventually to osteoarthritis. A target joint requires urgent and comprehensive treatment, especially in young patients, if permanent damage is to be prevented. Treatment with factor concentrate prophylaxis and physiotherapy can help to prevent new bleeds and allow the synovitis to resolve, but for persistent synovitis, synovectomy is recommended. The target ankle joint is a special challenge as it often develops in very young children when the articular cartilage is susceptible and compliance with conservative treatment is difficult.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479389     DOI: 10.1111/j.1365-2516.2004.00976.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  13 in total

1.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

2.  [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].

Authors:  Shi-Qiu Qiu; Jin-Mu Zhuang; Xuan Zhou; Rui-Xue Yin; Zhu-Qin Liu; Fei Ma; Ying-Jia Li; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

3.  Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Authors:  Junjiang Sun; Narine Hakobyan; Leonard A Valentino; Brian L Feldman; R Jude Samulski; Paul E Monahan
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

4.  Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY).

Authors:  Silvia Riva; Monika Bullinger; Edda Amann; Sylvia von Mackensen
Journal:  Health Qual Life Outcomes       Date:  2010-11-25       Impact factor: 3.186

5.  Initial joint bleed volume in a delayed on-demand treatment setup correlates with subsequent synovial changes in hemophilic mice.

Authors:  Kåre Kryger Vøls; Mads Kjelgaard-Hansen; Carsten Dan Ley; Axel Kornerup Hansen; Maj Petersen
Journal:  Animal Model Exp Med       Date:  2020-06-03

Review 6.  Comparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors.

Authors:  Mina Golestani; Peyman Eshghi; Hamid Reza Rasekh; Abdol Majid Cheraghali; Jamshid Salamzadeh; Ali Imani
Journal:  Iran Red Crescent Med J       Date:  2014-12-06       Impact factor: 0.611

7.  The relationship between target joints and direct resource use in severe haemophilia.

Authors:  Jamie O'Hara; Shaun Walsh; Charlotte Camp; Giuseppe Mazza; Liz Carroll; Christina Hoxer; Lars Wilkinson
Journal:  Health Econ Rev       Date:  2018-01-16

8.  The impact of severe haemophilia and the presence of target joints on health-related quality-of-life.

Authors:  Jamie O'Hara; Shaun Walsh; Charlotte Camp; Giuseppe Mazza; Liz Carroll; Christina Hoxer; Lars Wilkinson
Journal:  Health Qual Life Outcomes       Date:  2018-05-02       Impact factor: 3.186

9.  In vivo fluorescence molecular tomography of induced haemarthrosis in haemophilic mice: link between bleeding characteristics and development of bone pathology.

Authors:  K K Vøls; M Kjelgaard-Hansen; C D Ley; A K Hansen; M Petersen
Journal:  BMC Musculoskelet Disord       Date:  2020-04-14       Impact factor: 2.362

10.  The cost of severe haemophilia in Europe: the CHESS study.

Authors:  Jamie O'Hara; David Hughes; Charlotte Camp; Tom Burke; Liz Carroll; Daniel-Anibal Garcia Diego
Journal:  Orphanet J Rare Dis       Date:  2017-05-31       Impact factor: 4.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.